3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Head & Neck
2
Gynecologic
2
Gastrointestinal
2
Tumor-Agnostic
1
Lymphoid
1
Genitourinary
1
Dermatologic
1
Breast
1
Conditions
Neoplasms
21
Neoplasm Metastasis
10
Neoplasms, Unknown Primary
1
Carcinoma, Squamous Cell
1
Carcinoma
1
Adenocarcinoma
1
Interventions
Paclitaxel
9
Carboplatin
9
pembrolizumab
7
Radiotherapy
7
Cisplatin
5
Axitinib
4
Pemetrexed
3
Nivolumab
3
trifluridine tipiracil drug combination
2
regorafenib
2
osimertinib
2
fludarabine
2
dacomitinib
2
catumaxomab
2
Trastuzumab
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Nurses
2
Interleukin-2
2
Gemcitabine
2
Docetaxel
2
Cyclophosphamide
2
Cetuximab
2
Bevacizumab
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
vatalanib
1
temsirolimus
1
sovateltide
1
selinexor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
atezolizumab
×
Tumor-Agnostic
×
Clear all
NCT02367781
2021-08-09
IMpower130
Hoffmann-La Roche
Phase 3
Completed
723 enrolled
28 charts
1 FDA